垂体中心肢端肥大症多模式治疗的生化控制及随时间变化
该回顾性研究纳入409例肢端肥大症患者,其中266例有术后至少1年数据并至少2次随访,分析长期多模式治疗下IGF-1正常化率及治疗模式变化。结果显示93.2%患者在9.9年随访中达到IGF-1正常,2006年后首次IGF-1正常时间缩短,放疗和再次手术使用减少。
要点
- 多模式治疗下93.2%肢端肥大症患者可达IGF-1正常。
- 2006年后首次IGF-1正常时间缩短至14.0个月。
- 放疗和再次手术使用率随时间下降。
核心结论
- 绝大多数肢端肥大症患者在当前时代可通过多模式治疗实现生化控制。
- 放疗和重复垂体手术的使用随时间减少。
- 术后未用辅助治疗的长期IGF-1控制有所改善。
研究设计与样本
- 回顾性研究,纳入409例肢端肥大症患者,其中266例纳入长期分析(术后至少1年数据且至少2次后续门诊随访)。
- 诊断时平均年龄43.4(标准差14.3)岁,BMI中位数28.5(IQR 24.9-32.1)kg/m2,IGF-1指数中位数2.3(IQR 1.7-3.1),80.5%为大腺瘤。
主要发现
- 总体(N=266)在9.9(IQR 5.0-15.0)年多模式治疗中,93.2%达到IGF-1正常。
- 手术未缓解后首次IGF-1正常时间:2006年后14.0个月(95%CI 10.0-20.0) vs 2006年前27.5个月(95%CI 22.0-36.0),P=0.002。
- 2006年后放疗28例(22%) vs 前62例(47.0%),P<0.001;再次手术12例(9.4%) vs 前28例(21.2%),P=0.010。
- 2006年后经蝶手术患者年龄更大(46.6±14.3 vs 40.0±13.4岁,P<0.001),年龄与肿瘤大小呈负相关。
- 男性、年龄较大、肿瘤较小、诊断时IGF-1指数较低预测术后未用辅助治疗的长期持续IGF-1控制。
临床怎么用
- 对肢端肥大症患者应采用多模式治疗以实现IGF-1正常化。
- 2006年后放疗和再次手术的使用减少,可更多依赖药物等辅助治疗。
- 男性、老年、小肿瘤、低IGF-1指数患者术后可能无需辅助治疗即可长期控制。
局限性
- 回顾性研究设计。
- 单中心数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the prevalence of insulin-like growth factor-1 (IGF-1) normalization with long-term multimodality therapy in a pituitary center and to assess changes over time. METHODS: Patients with acromegaly (N = 409), with ≥1 year of data after surgery and at least 2 subsequent clinic visits were included in long-term analysis (N = 266). Biochemical data, clinical characteristics, and therapeutic interventions were reviewed retrospectively. RESULTS: At diagnosis, mean [standard deviation] age was 43.4 [14.3] years, body mass index was 28.5 (24.9-32.1) kg/m2 (median, interquartile range), serum IGF-1 index (IGF-1 level/upper limit of normal) was 2.3 [1.7-3.1], and 80.5% had macroadenomas. Patients with transsphenoidal surgery after 2006 were older [46.6 ± 14.3 vs 40.0 ± 13.4 years; P < 0.001]. Age and tumor size correlated inversely. Overall (N = 266), 93.2% achieved a normal IGF-1 level during 9.9 [5.0-15.0] years with multimodality therapy. The interval to first normal IGF-1 level following failed surgical remission was shorter after 2006: 14.0 (95% confidence interval, 10.0-20.0) versus 27.5 (22.0-36.0) months (P = 0.002). Radiation therapy and second surgery were rarer after 2006: 28 (22%) versus 62 (47.0%); P < 0.001 and 12 (9.4%) versus 28 (21.2%); P = 0.010, respectively. Age at diagnosis increased over time periods, possibly reflecting increased detection of acromegaly in older patients with milder disease. Male gender, older age, smaller tumor and lower IGF-1 index at diagnosis predicted long-term sustained IGF-1 control after surgery without adjuvant therapies. CONCLUSION: The vast majority of patients with acromegaly can be biochemically controlled with multimodality therapy in the current era. Radiotherapy and repeat pituitary surgery became less frequently utilized over time. Long-term postoperative IGF-1 control without use of adjuvant therapies has improved.
引用
- Ghajar A, Jones PS, Guarda FJ, et al. Biochemical Control in Acromegaly With Multimodality Therapies: Outcomes From a Pituitary Center and Changes Over Time. J Clin Endocrinol Metab. 2020. PMID: 31701145. doi:10.1210/clinem/dgz187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。